Galectin Therapeutics Receives Patent

Galectin Therapeutics has received a U.S. Patent for “Method of Enhancing Specific Immunotherapies in Cancer Treatment.” Members of Galectin and Providence Cancer Center in Portland, Ore. are joint inventors on the patent, and Galectin holds the exclusive license. The patent’s principal claims cover method of use of GR-MD-02 as a means to enhance anti-tumor activity and increase survival effects of combining GR-MD-02 with multiple clinically relevant types of immune modulators, such as Keytruda; and for multiple types of cancer.

The patent provides intellectual property protection for the ongoing human trial that evaluates the effect of the combination of GR-MD-02 with approved cancer immunotherapy drugs.

Leave a Comment